Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KLK7 | P49862 | 2/20 | 0.64 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801427 | 1.00 | MAPT (0.66) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL5425736 | 0.97 | MAPT (0.62) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL5425732 | 0.97 | MAPT (0.62) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL5332690 | 0.96 | SIRT2 (0.65) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL5332693 | 0.96 | SIRT2 (0.65) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL17073778 | 0.93 | CTSL (0.64) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL30340359 | 0.92 | MAPT (0.60) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL17309872 | 0.91 | MAPT (0.68) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL2334319 | 0.91 | MAPT (0.68) | MAPTKLK7KLK5SIRT2ITGB3 | |
| SCHEMBL2334326 | 0.91 | MAPT (0.68) | MAPTKLK7KLK5SIRT2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | SEASUNBIO MATERIALS (KP) | 2023-04-06 | — | — | US | disclosed |
| EP-4083054-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | Seasunbio Materials (KR) | 2022-11-02 | — | — | EP | disclosed |
| EP-3383846-B1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | OTAGO INNOVATION LTD (NZ) | 2022-06-22 | — | — | EP | disclosed |
| US-11072584-B2 | Carbon monoxide releasing norbornenone compounds | OTAGO INNOVATION LIMITED (NZ) | 2021-07-27 | — | — | US | disclosed |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200109115-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-04-09 | — | — | US | disclosed |
| US-20180346420-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | UNIVERSITY OF OTAGO (NZ) | 2018-12-06 | — | — | US | disclosed |
| EP-3383846-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | Sammut, Ivan Andrew (NZ) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095237-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | SAMMUT IVAN ANDREW (NZ) | 2017-06-08 | — | — | WO | disclosed |
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| EP-1850878-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | NCL, POLI, RNGTT | MAPT 1675/4885KLK7 620/4885KLK5 1890/4885 |
| US-20200109115-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | HMOX1, MB, NOS2 | MAPT 4693/4885KLK7 4255/4885KLK5 3996/4885 |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | MAPT 3874/4885KLK7 2695/4885KLK5 3402/4885 |
| US-20180346420-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | HMOX1, MB, NOS2 | MAPT 4693/4885KLK7 4255/4885KLK5 3996/4885 |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | ABAT, SSBP1, PDF | MAPT 2437/4885KLK7 4579/4885KLK5 4576/4885 |
| US-11072584-B2 | Carbon monoxide releasing norbornenone compounds | HMOX1, MB, NOS2 | MAPT 4693/4885KLK7 4255/4885KLK5 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.